Immunic (IMUX) director Nagel received 25,370 Stock Option
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Robert Thorvald Nagel (director at Immunic Inc., IMUX) reported that they received 25,370 Stock Option on Sep 16, 2026.
- Reporting person
- Nagel Robert Thorvald
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 16, 2026 | Grant or award (A) | Stock OptionOn 25,370 Common Stock1, 2 | +25,370 | - | - | 25,370 direct |
Holdings before and after
- Stock Option: 0 to 25,370 direct
Footnotes from the filing
- 1. The option vests in monthly increments over a period of one year from the grant date.
- 2. The Reporting Person is a member of BVF Partners L.P. ( BVF ) and is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the equity grants to BVF. As such, the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Nagel report in this IMUX Form 4?
Robert Thorvald Nagel (director at Immunic Inc., IMUX) reported that they received 25,370 Stock Option on Sep 16, 2026.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for IMUX
Across the 29 sessions after earlier IMUX headlines, the stock closed higher 18 times and lower 10 times, with a median move of 4.5% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IMUX | SPY |
|---|---|---|---|
| Sep 2, 2026 | Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026 | -2.3% | +0.4% |
| Sep 1, 2026 | Immunic Appoints Chitrang Davé as Chief Data and Digital Officer | -7.7% | -0.7% |
| Aug 17, 2026 | Wedbush initiated coverage on Immunic with a new price target | -0.2% | -0.5% |
| Aug 11, 2026 | Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Updateand 1 other headline that session | +9.8% | -0.3% |
| Jul 9, 2026 | Immunic to Participate in Investor Conferences in July | +0.1% | +0.8% |
| Jun 10, 2026 | Immunic to Participate in Investor, Industry and Scientific Conferences in June | -4.5% | -1.6% |
Earlier insider filings at IMUX
- Sep 18, 2026SEC Form 4 filed by See Explanation of Responses Bvf Partners L P/Il
- Aug 10, 2026SEC Form 4 filed by Director Ridloff Elena
- Jul 7, 2026SEC Form 4 filed by Director Skerjanec Simona
- Jul 7, 2026SEC Form 4 filed by Director Rudick Richard Alan
- Jul 7, 2026SEC Form 4 filed by Director Phillips Barclay A
Quantisnow market dataNASDAQ
IMUX
Immunic Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2014
Get push alerts for IMUX
Full IMUX profile on Quantisnow Follow IMUX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time